(Adds shares in paragraph 2, details on disease in paragraph 3 and 4, background in paragraphs 5-7)
Sept 19 (Reuters) - The U.S. Food and Drug Administration has declined to approve Vanda Pharmaceuticals'
drug to treat stomach paralysis symptoms, the company said on Thursday.
Shares of the company fell about 14% to $4.26 in premarket trading.
Vanda was seeking the health regulator's nod for the drug tradipitant to treat gastroparesis, a condition characterized by delayed gastric emptying.
The disease is associated with symptoms such as severe nausea, vomiting, and difficulty finishing a normal meal.
Vanda licensed tradipitant from Eli Lilly and is also studying it for motion sickness.
The health regulator had imposed a partial clinical hold on tradipitant, preventing trials longer than 12 weeks.
The company plans to submit a separate application for the drug to prevent vomiting in motion sickness later this year.
(Reporting by Sriparna Roy in Bengaluru; Editing by Abinaya Vijayaraghavan)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.